{"id":"gemox","safety":{"commonSideEffects":[{"rate":"30%","effect":"Neutropenia"},{"rate":"20%","effect":"Nausea and vomiting"},{"rate":"15%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Gemcitabine and oxaliplatin combination chemotherapy is a chemotherapy regimen that uses the drugs gemcitabine and oxaliplatin to kill cancer cells. Gemcitabine is a nucleoside analog that interferes with DNA synthesis, while oxaliplatin is a platinum-based drug that cross-links DNA, causing DNA damage and apoptosis in cancer cells.","oneSentence":"Gemcitabine and oxaliplatin combination chemotherapy","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:37:59.760Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"}]},"trialDetails":[{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT06314334","phase":"PHASE2","title":"Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-04","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":210},{"nctId":"NCT04384484","phase":"PHASE3","title":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ADC Therapeutics S.A.","startDate":"2020-09-16","conditions":"Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":440},{"nctId":"NCT03570892","phase":"PHASE3","title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":"Non-Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT07480850","phase":"PHASE2","title":"Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":40},{"nctId":"NCT07472621","phase":"","title":"Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-03-10","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":20},{"nctId":"NCT02386397","phase":"PHASE1, PHASE2","title":"Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2014-09","conditions":"Digestive Cancer","enrollment":66},{"nctId":"NCT05171647","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-04-25","conditions":"Non-Hodgkin Lymphoma","enrollment":208},{"nctId":"NCT07451652","phase":"PHASE2","title":"Low Dose Epcoritamab Plus GemOx in R/R DLBCL","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2026-02","conditions":"Relapsed/Refractory Diffuse Large B Cell Lymphoma","enrollment":10},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT06508658","phase":"PHASE3","title":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-08-13","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":360},{"nctId":"NCT04542824","phase":"PHASE1, PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma","enrollment":78},{"nctId":"NCT04628494","phase":"PHASE3","title":"A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2021-01-13","conditions":"Diffuse Large B-cell Lymphoma","enrollment":484},{"nctId":"NCT07226752","phase":"PHASE3","title":"A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2022-10-08","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":72},{"nctId":"NCT04127227","phase":"PHASE2","title":"Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-10-09","conditions":"NK/T Cell Lymphoma Nos","enrollment":34},{"nctId":"NCT06806033","phase":"PHASE2","title":"A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-03-05","conditions":"B-Cell Non-Hodgkins Lymphoma","enrollment":100},{"nctId":"NCT05286814","phase":"PHASE2","title":"PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-24","conditions":"Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer","enrollment":70},{"nctId":"NCT07409428","phase":"PHASE3","title":"A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Hutchmed","startDate":"2026-03-10","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":240},{"nctId":"NCT05451290","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-11-01","conditions":"Advanced Biliary Tract Carcinoma","enrollment":30},{"nctId":"NCT05430698","phase":"PHASE2","title":"PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-01-31","conditions":"Perihilar Cholangiocarcinoma","enrollment":62},{"nctId":"NCT07389356","phase":"NA","title":"Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-25","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":70},{"nctId":"NCT07385989","phase":"PHASE2","title":"Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"WEI XU","startDate":"2026-01-25","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":40},{"nctId":"NCT06904170","phase":"PHASE2, PHASE3","title":"Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-14","conditions":"Hepatocellular Carcinoma","enrollment":196},{"nctId":"NCT06313203","phase":"PHASE2","title":"HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-02-13","conditions":"Intrahepatic Cholangiocarcinoma, Chemotherapy Effect","enrollment":39},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT03092895","phase":"PHASE2","title":"A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-04-24","conditions":"Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma","enrollment":157},{"nctId":"NCT07365306","phase":"PHASE2","title":"Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-12-30","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma","enrollment":43},{"nctId":"NCT05668884","phase":"PHASE2","title":"GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-10-18","conditions":"Biliary Tract Carcinoma","enrollment":93},{"nctId":"NCT04408638","phase":"PHASE3","title":"A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-02-23","conditions":"Diffuse Large B-cell Lymphoma","enrollment":270},{"nctId":"NCT05348811","phase":"PHASE2","title":"HAIC Combined With Donafenib and Sintilimab for Unresectable ICC","status":"COMPLETED","sponsor":"Zhongda Hospital","startDate":"2022-06-13","conditions":"Cholangiocarcinoma","enrollment":25},{"nctId":"NCT04425070","phase":"PHASE1, PHASE2","title":"A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma","status":"TERMINATED","sponsor":"Antengene Corporation","startDate":"2020-08-18","conditions":"Peripheral T-cell Lymphoma, NK/T-cell Lymphoma","enrollment":56},{"nctId":"NCT07093710","phase":"PHASE1, PHASE2","title":"Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-27","conditions":"Peripheral T Cell Lymphoma","enrollment":101},{"nctId":"NCT07304388","phase":"PHASE2","title":"HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2023-02-10","conditions":"Intrahepatic Cholangiocarcinoma (Icc)","enrollment":96},{"nctId":"NCT04182204","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-07","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":270},{"nctId":"NCT03533582","phase":"PHASE3","title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-24","conditions":"Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma","enrollment":537},{"nctId":"NCT07279584","phase":"PHASE2","title":"Golidocitinib Combined With GemOx in RR PTCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-12-20","conditions":"Peripheral T-cell Lymphomas (PTCL)","enrollment":31},{"nctId":"NCT06230471","phase":"PHASE2","title":"Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-01-09","conditions":"Biliary Tract Neoplasms Immunotherapy","enrollment":60},{"nctId":"NCT07267078","phase":"PHASE2","title":"Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-05-25","conditions":"Biliary Tract Cancer","enrollment":45},{"nctId":"NCT07263360","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-01","conditions":"BTC","enrollment":29},{"nctId":"NCT06925516","phase":"PHASE2","title":"A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-01-22","conditions":"Intrahepatic Cholangiocarcinoma (Icc)","enrollment":38},{"nctId":"NCT04891289","phase":"PHASE2","title":"Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-07","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":164},{"nctId":"NCT03217097","phase":"NA","title":"MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-10-16","conditions":"Neuroendocrine Tumors","enrollment":116},{"nctId":"NCT06929624","phase":"PHASE3","title":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-04-24","conditions":"Diffuse Large B-cell Lymphoma","enrollment":280},{"nctId":"NCT07208526","phase":"NA","title":"A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Conversion Therapy, TDTP-RECIST","enrollment":270},{"nctId":"NCT04607772","phase":"PHASE1, PHASE2","title":"Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-11-18","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT07184788","phase":"PHASE2","title":"G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Navy General Hospital, Beijing","startDate":"2025-10-01","conditions":"Aggressive B-Cell Lymphoma","enrollment":80},{"nctId":"NCT04669496","phase":"PHASE2, PHASE3","title":"Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-01-20","conditions":"Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib","enrollment":178},{"nctId":"NCT07059650","phase":"PHASE1, PHASE2","title":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","status":"RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2025-08-19","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":150},{"nctId":"NCT07081022","phase":"PHASE2","title":"JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-08-17","conditions":"B-cell Non-Hodgkin's Lymphoma","enrollment":180},{"nctId":"NCT07122609","phase":"PHASE2","title":"Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-08-05","conditions":"Relapsed and Refractory DLBCL","enrollment":22},{"nctId":"NCT04984837","phase":"PHASE2","title":"Study of Lacutamab in Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-10-05","conditions":"Peripheral T Cell Lymphoma, Relapse/Recurrence","enrollment":56},{"nctId":"NCT06892925","phase":"PHASE2","title":"QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors","status":"RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2025-06-14","conditions":"Biliary Tract Tumors","enrollment":59},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT06643208","phase":"","title":"D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC","status":"RECRUITING","sponsor":"Fujian Provincial Hospital","startDate":"2024-07-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":37},{"nctId":"NCT06370663","phase":"PHASE2","title":"First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC","status":"TERMINATED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-04-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":1},{"nctId":"NCT07001540","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-05-08","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":130},{"nctId":"NCT06601504","phase":"PHASE2","title":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hutchmed","startDate":"2024-11-05","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":61},{"nctId":"NCT06953739","phase":"PHASE3","title":"A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-05-01","conditions":"NK-T-Cell Lymphoma, Extranodal","enrollment":60},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT06941688","phase":"PHASE2","title":"Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma","status":"TERMINATED","sponsor":"Seoul National University Hospital","startDate":"2020-11-13","conditions":"Peripheral T-cell Lymphoma (PTCL)","enrollment":17},{"nctId":"NCT05342194","phase":"PHASE3","title":"Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-06-19","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":480},{"nctId":"NCT04365036","phase":"PHASE3","title":"A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-05-03","conditions":"NK/T Cell Lymphoma Nos","enrollment":207},{"nctId":"NCT06208462","phase":"PHASE2","title":"Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-19","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":33},{"nctId":"NCT06852287","phase":"PHASE2","title":"Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-09-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Gall Bladder Cancer","enrollment":33},{"nctId":"NCT06824883","phase":"PHASE2","title":"Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-05-20","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":49},{"nctId":"NCT05557578","phase":"PHASE2","title":"GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-05-05","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":20},{"nctId":"NCT04361331","phase":"PHASE2","title":"Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-03-06","conditions":"Cholangiocarcinoma, Intrahepatic","enrollment":61},{"nctId":"NCT06718257","phase":"","title":"Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-09-01","conditions":"Cholangiocarcinoma","enrollment":300},{"nctId":"NCT03366272","phase":"PHASE2, PHASE3","title":"Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2017-12-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":348},{"nctId":"NCT06792253","phase":"PHASE3","title":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"BeBetter Med Inc","startDate":"2025-01-06","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":416},{"nctId":"NCT06778902","phase":"PHASE2","title":"AZA Combined with R-GemOx for Elderly DLBCL Patients","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2025-02-01","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":80},{"nctId":"NCT06654947","phase":"PHASE2","title":"A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-01","conditions":"Biliary Tract Cancer","enrollment":23},{"nctId":"NCT05215665","phase":"NA","title":"GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-01-15","conditions":"Cholangiocarcinoma","enrollment":146},{"nctId":"NCT06192797","phase":"PHASE2","title":"Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-06-11","conditions":"Cholangiocarcinoma Non-resectable","enrollment":36},{"nctId":"NCT06583083","phase":"PHASE2","title":"Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-22","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":84},{"nctId":"NCT04183712","phase":"PHASE2","title":"Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-06-01","conditions":"Gallbladder Carcinoma","enrollment":102},{"nctId":"NCT02692248","phase":"PHASE2","title":"Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2016-04-07","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":64},{"nctId":"NCT06573151","phase":"PHASE2","title":"Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-09-01","conditions":"Lymphoma","enrollment":28},{"nctId":"NCT05833815","phase":"PHASE2, PHASE3","title":"Addition of Everolimus to Standard of Care in Carcinoma Gallbladder","status":"RECRUITING","sponsor":"Banaras Hindu University","startDate":"2022-11-01","conditions":"Gallbladder Cancer","enrollment":56},{"nctId":"NCT06505486","phase":"","title":"GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-07-10","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":21},{"nctId":"NCT06489808","phase":"PHASE2","title":"Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-28","conditions":"Relapsed/Refractory Large B-Cell Lymphoma","enrollment":89},{"nctId":"NCT06417606","phase":"PHASE4","title":"Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhiyong Huang","startDate":"2024-05-30","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":20},{"nctId":"NCT06423170","phase":"PHASE2","title":"A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-06-01","conditions":"Unresectable Gallbladder Cancer","enrollment":37},{"nctId":"NCT03017326","phase":"PHASE3","title":"Paediatric Hepatic International Tumour Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2017-08-24","conditions":"Hepatoblastoma, Carcinoma, Hepatocellular","enrollment":450},{"nctId":"NCT01626664","phase":"PHASE2","title":"KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2012-06","conditions":"Adult T-cell Leukemia-Lymphoma","enrollment":71},{"nctId":"NCT06362317","phase":"PHASE2","title":"Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-03-06","conditions":"Biliary Tract Neoplasms Immunotherapy","enrollment":300},{"nctId":"NCT06335927","phase":"PHASE2","title":"HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-05-11","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":45},{"nctId":"NCT04313608","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-06-04","conditions":"B-cell Lymphoma","enrollment":23},{"nctId":"NCT06320301","phase":"PHASE2","title":"Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-04-01","conditions":"Biliary Tract Cancer, Gemox Chemotherapy","enrollment":43},{"nctId":"NCT06164327","phase":"PHASE1","title":"Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"UNKNOWN","sponsor":"BeBetter Med Inc","startDate":"2023-12-01","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":75},{"nctId":"NCT05935579","phase":"PHASE2","title":"Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-12-14","conditions":"Biliary Tract Neoplasms, Immunotherapy","enrollment":40},{"nctId":"NCT06013943","phase":"PHASE2","title":"Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC","status":"UNKNOWN","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2023-03-17","conditions":"Gallbladder Cancer","enrollment":30},{"nctId":"NCT06033118","phase":"PHASE1, PHASE2","title":"Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2023-10-01","conditions":"Combined Hepatocellular Cholangiocarcinoma","enrollment":25},{"nctId":"NCT04022005","phase":"PHASE2","title":"Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2019-06-19","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":54},{"nctId":"NCT05156788","phase":"PHASE2","title":"Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-12-12","conditions":"Biliary Tract Cancer, PD-1 Antibody, Gemox","enrollment":40},{"nctId":"NCT05919095","phase":"PHASE2","title":"A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-06-30","conditions":"Unresectable Gallbladder Cancer","enrollment":37},{"nctId":"NCT05786989","phase":"PHASE4","title":"Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Chongqing University Cancer Hospital","startDate":"2023-02-28","conditions":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","enrollment":32},{"nctId":"NCT05620498","phase":"PHASE2","title":"Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-09-08","conditions":"Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","enrollment":60},{"nctId":"NCT05350943","phase":"PHASE2","title":"HAIC Combined With Toripalimab and Donafenib for Advanced BTC","status":"UNKNOWN","sponsor":"Lu Wang, MD, PhD","startDate":"2022-03-01","conditions":"Biliary Tract Adenocarcinoma","enrollment":70},{"nctId":"NCT05036798","phase":"PHASE2","title":"Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-09-17","conditions":"Potentially Resectable Locally Advanced Malignant Tumors of Biliary System","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":311,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gemcitabine plus oxaliplatin","Gemcitabine","Oxaliplatin"],"phase":"phase_2","status":"active","brandName":"GEMOX","genericName":"GEMOX","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemcitabine and oxaliplatin combination chemotherapy Used for Colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}